NKGen Biotech, Inc.
NKGNDelisted Jul 17, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001845459
NKGen Biotech, Inc. was delisted on Jul 17, 2025; its insiders filed their last Form 4 on Jun 2, 2025; no institution reported holding it in 13F filings for Q2 2025; no superinvestor held it.
13F holders, Q4 2024
Institutional positions in NKGen Biotech, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +6 vs. Q3 2024
- Shares held
- 8.35M
- +4.60M (+122.5%) vs. Q3 2024
- Total value
- $5.07M
- +$3.84M (+312.2%) vs. Q3 2024
- New holders
- 9
- 4 more added
- Sold out
- 3
- 5 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NKGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $165.4K |
| Q1 2026 | 1 | $192.9K |
| Q4 2025 | 1 | $137.8K |
| Q3 2025 | 1 | $303.2K |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 3 | $160.8K |
| Q4 2024 | 25 | $5.07M |
| Q3 2024 | 19 | $1.23M |
| Q2 2024 | 17 | $4.24M |
| Q1 2024 | 13 | $5.66M |
| Q4 2023 | 9 | $13.7M |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding NKGen Biotech, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Pathstone Holdings, LLC | 2,797,661 | $1.83M | 0.01% | +2,797,661 | New |
| Meteora Capital, LLC | 2,772,145 | $1.82M | 0.65% | +1,887,400+213.3% | Added |
| University of Chicago | 550,000 | $360.4K | 0.34% | 00.0% | Unchanged |
| Diametric Capital, LP | 518,134 | $339.5K | 0.23% | 00.0% | Unchanged |
| Kepos Capital LP | 230,022 | $151.0K | 0.13% | +230,022 | New |
| Vanguard Group Inc | 227,804 | $149.2K | 0.00% | 00.0% | Unchanged |
| Sequoia Financial Advisors, LLC | 156,000 | $102.2K | 0.00% | +87,000+126.1% | Added |
| Magnetar Financial LLC | 267,508 | $95.5K | 0.00% | +267,508 | New |
| Geode Capital Management, LLC | 127,168 | $83.3K | 0.00% | +14,454+12.8% | Added |
| Advisory Research Inc | 43,088 | $28.2K | 0.00% | +43,088 | New |
| XTX Topco Ltd | 33,625 | $22.0K | 0.00% | +33,625 | New |
| Northern Trust Corp | 29,082 | $19.1K | 0.00% | 00.0% | Unchanged |
| Periscope Capital Inc. | 25,000 | $16.4K | 0.01% | +25,000 | New |
| Two Sigma Securities, LLC | 22,495 | $14.7K | 0.00% | −1,980−8.1% | Reduced |
| Two Sigma Investments, LP | 22,356 | $14.6K | 0.00% | +22,356 | New |
| SkyOak Wealth, LLC | 13,164 | $8.63K | 0.00% | +13,164 | New |
| State Street Corp | 11,200 | $7.34K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 2,782 | $1.82K | 0.00% | −8,953−76.3% | Reduced |
| BlackRock, Inc. | 1,854 | $1.22K | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 902 | $591 | 0.00% | +902 | New |
| UBS Group AG | 763 | $500 | 0.00% | −13,883−94.8% | Reduced |
| Federation des caisses Desjardins du Quebec | 500 | $328 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 102 | $67 | 0.00% | −4−3.8% | Reduced |
| JPMorgan Chase & Co | 45 | $29 | 0.00% | +14+45.2% | Added |
| Polar Asset Management Partners Inc. | 500,000 | $0 | 0.00% | −681,872−57.7% | Reduced |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −95,438−100.0% | Sold out |
| Towneley Capital Management, Inc | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −10,318−100.0% | Sold out |